share_log
Breakings ·  Dec 31, 2024 08:30
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination With Defactinib for the Treatment of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment